Overview
- IndustryMedicinal Chemicals & Botanical Products1
- HeadquartersWanchai, Hong Kong1
- Incorporated inCayman Islands3
- Business addressSuite 901, Tesbury Centre,, 28 Queen'S Road East, Wanchai, K3 000003
- Filer categoryNon-accelerated filer, Emerging growth company3
See how the biggest companies compare on our leaderboards
Shuju Chen, respectively. After these Share transfers, Zhong Yuan Investment does not hold any Shares of the Company.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Cost of revenue9¢$206.4K
- Research and development22¢$493.8K
- Other costs54¢$1.2M
- Interest4¢$81.3K
- Income tax0¢$594
- Profit12¢$271.9K
Out of $2.3M in revenue.2
Financial statements
No quarterly figures reported.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.2M5 | $1.2M6 | $1.6M2 | $2.3M2 | $1.7M2 | $2.3M2 | |
| Cost of revenue | $320.8K5 | $257.0K6 | $282.0K2 | $847.0K2 | $144.7K2 | $206.4K2 | |
| Gross profit | $896.8K5 | $962.6K6 | $1.4M2 | $1.5M2 | $1.5M7 | ||
| Research and development | $42.7K5 | $182.3K6 | $211.0K2 | $680.3K2 | $526.8K2 | $493.8K2 | |
| Operating expenses | $2.6M7 | $3.3M2 | $2.0M2 | ||||
| Operating income | $312.1K5 | -$85.5K6 | -$14.6K2 | -$1.1M2 | -$1.6M2 | $266.6K2 | |
| Interest | $20.1K5 | $6.1K6 | -$24.6K2 | -$35.4K2 | $46.7K2 | $81.3K2 | |
| Income before tax | $1.1M2 | -$2.2M2 | $271.3K2 | ||||
| Income tax | $15.9K5 | $06 | $02 | $11.1K2 | -$8.8K2 | -$5942 | |
| Net income | $280.2K5 | -$87.3K6 | -$28.0K2 | -$1.1M2 | -$2.2M2 | $271.9K2 | |
| Earnings per share | $0.162 | $0.122 | -$0.022 | ||||
| Earnings per share (diluted) | $0.162 | $0.122 | -$0.022 | ||||
| Shares (weighted, basic) | 17.3M shares7 | 17.7M shares2 | 17.7M shares2 | ||||
| Shares (weighted, diluted) | 17.3M shares7 | 17.7M shares2 | 18.0M shares2 |
No quarterly figures reported.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash | $60.8K2 | $194.6K2 | $101.5K2 | $277.8K2 | $145.3K2 | ||
| Receivables | $194.1K2 | $353.7K2 | $790.6K2 | ||||
| Inventory | $1.2M2 | $131.5K2 | $29.7K2 | ||||
| Current assets | $1.9M5 | $1.5M6 | $2.4M2 | $2.1M2 | $1.0M2 | $2.0M2 | |
| Property, plant and equipment | $10.7K2 | $4.8K2 | $2.4K2 | ||||
| Total assets | $1.9M5 | $2.3M6 | $3.5M2 | $2.9M2 | $2.1M2 | $3.2M2 | |
| Short-term debt | $462.0K2 | $1.4M2 | $1.6M2 | ||||
| Current liabilities | $423.6K5 | $628.7K6 | $761.2K2 | $835.6K2 | $2.2M2 | $2.5M2 | |
| Long-term debt | $1.9M2 | ||||||
| Long-term liabilities | $1.1M2 | $608.1K2 | $904.3K2 | ||||
| Total liabilities | $423.6K5 | $799.6K6 | $2.0M2 | $1.9M2 | $2.8M2 | $3.4M2 | |
| Retained earnings | -$1.4M2 | -$3.5M2 | -$3.2M2 | ||||
| Shareholders’ equity | $1.2M5 | $1.5M6 | $1.5M8 | $1.5M2 | $941.4K2 | -$698.9K2 | -$204.5K2 |
| Shares outstanding | 161.5M shares5 | 171.4M shares5 | 17.1M shares6 | 17.5M shares8 | 17.7M shares7 | 17.7M shares2 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash from operations | $757.5K5 | -$146.6K6 | $309.2K2 | -$255.7K2 | -$1.0M2 | -$745.8K2 | |
| Depreciation and amortization | $4.7K2 | $3.7K2 | $2.0K2 | ||||
| Stock-based compensation | $318.1K2 | $54.5K2 | $02 | ||||
| Capital spending | $05 | $7.6K6 | $5.6K2 | $02 | $22.4K2 | ||
| Free cash flow | $757.5K | -$154.1K | $303.6K | -$255.7K | -$1.0M | ||
| Cash from investing | $02 | $118.1K2 | |||||
| Cash from financing | $263.0K2 | $1.3M2 | $715.1K2 |
Compare Zhong Yuan Bio-Technology Holdings Ltd with another company
Corporate structure
Zhong Yuan Bio-Technology Holdings Ltd sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Zhong Yuan Bio-Technology Holdings Ltd
- Xianyang Chen Filed SC 13D on Zhong Yuan Bio-Technology Holdings Ltd, latest Mar 7, 2024
- Yu Chang Filed SC 13D on Zhong Yuan Bio-Technology Holdings Ltd, latest Mar 7, 2024
- Tingting Chang Filed SC 13D/A on Zhong Yuan Bio-Technology Holdings Ltd, latest Jan 25, 2024 (3 filings since Jan 24, 2024)
- Fung-Ming Pang Filed SC 13D on Zhong Yuan Bio-Technology Holdings Ltd, latest Jan 24, 2024
- Prime Legend Ltd Filed SC 13D on Zhong Yuan Bio-Technology Holdings Ltd, latest Jan 24, 2024
- Yau-Sing Tang Filed SC 13D on Zhong Yuan Bio-Technology Holdings Ltd, latest Jan 24, 2024
- Zhong Yuan Investment Ltd Filed SC 13D on Zhong Yuan Bio-Technology Holdings Ltd, latest Jan 24, 2024
- Zhong Yuan Bio-Technology Holdings Ltd Wanchai, Hong Kong
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Zhong Yuan Bio-Technology Holdings Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $18.6K2 Mar 31, 2024 | $22.4K2 Mar 31, 2023 | −16.8% |
| Accumulated depreciation | $16.2K2 Mar 31, 2024 | $17.6K2 Mar 31, 2023 | −7.9% |
| Property and equipment, net | $2.4K2 Mar 31, 2024 | $4.8K2 Mar 31, 2023 | −49.8% |
| Operating-lease assets (leased space) | $577.7K2 Mar 31, 2024 | $523.5K2 Mar 31, 2023 | +10.3% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Stakes in other companies (equity method) | $562.0K2 Mar 31, 2024 | $562.0K2 Mar 31, 2023 | 0% |
Inventory
Leadership
Who has led Zhong Yuan Bio-Technology Holdings Ltd, and when. Pick a name to see everywhere that person has worked.
- Chief executive officerTingting Chang Jun 6, 2017 to Jun 6, 20179
- PresidentJames M. Cassidy May 17, 2016 to May 17, 201610
Board members and other officers (4)
- Vice PresidentJames K. McKillop May 17, 2016 to May 17, 201611
- Board memberTingting Chang Jun 6, 2017 to Jun 6, 20179
- Board memberJames K. McKillop May 17, 2016 to May 17, 201611
- Board memberJames M. Cassidy May 17, 2016 to May 17, 201610
Former names
Timeline
- Jun 6, 2017New chief executive Tingting Chang becomes CEO9
Filings
56 filings to the SEC since October 2021: 4 annual reports, 9 large holders, 43 other. The latest 20:
- Jul 31, 2025NT 20-F NOTIFICATION OF LATE FILING EDGAR
- Nov 7, 202420-F EDGAR
- Aug 1, 2024NT 20-F NOTIFICATION OF LATE FILING EDGAR
- Jun 14, 20246-K EDGAR
- May 20, 2024F-1/A EDGAR
- Mar 26, 2024F-1/A EDGAR
- Mar 25, 20246-K EDGAR
- Mar 7, 2024SC 13D SCHEDULE 13D EDGAR
- Mar 7, 2024SC 13D SCHEDULE 13D EDGAR
- Jan 25, 2024SC 13D/A SCHEDULE 13D/A EDGAR
- Jan 25, 2024SC 13D/A SCHEDULE 13D/A EDGAR
- Jan 24, 2024SC 13D/A SCHEDULE 13D/A EDGAR
- Jan 24, 2024SC 13D SCHEDULE 13D EDGAR
- Jan 24, 2024SC 13D SCHEDULE 13D EDGAR
- Jan 24, 2024SC 13D SCHEDULE 13D EDGAR
- Jan 24, 2024SC 13D SCHEDULE 13D EDGAR
- Nov 13, 2023F-1/A EDGAR
- Oct 26, 20238-A12B EDGAR
- Oct 6, 2023F-1/A EDGAR
- Sep 14, 20236-K EDGAR
The 56 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Xianyang ChenSC 13D, 1 filing Mar 7, 202412
- Yu ChangSC 13D, 1 filing Mar 7, 202413
- Tingting ChangSC 13D/A, 3 filings Jan 24, 2024 to Jan 25, 202414
- Fung-Ming PangSC 13D, 1 filing Jan 24, 202415
- Prime Legend LtdSC 13D, 1 filing Jan 24, 202416
- Yau-Sing TangSC 13D, 1 filing Jan 24, 202417
- Zhong Yuan Investment LtdSC 13D, 1 filing Jan 24, 202418
SEC filer profile
How Zhong Yuan Bio-Technology Holdings Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARZhong Yuan Bio-Technology Holdings Ltd1
- CIK0001672886
- Employer ID (EIN)81-23109051
- Filer statusNon-accelerated filer an emerging growth company; not a shell company4
- Incorporated inCayman Islands4
- Fiscal year endsMarch 311
- Industry code (SIC)2833 Medicinal Chemicals & Botanical Products1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business addressSuite 901, Tesbury Centre,, 28 Queen'S Road East, Wanchai, K3 000001
- Phone011 852 2919-89161
- Shares outstanding17,709,718 shares as of Mar 31, 20244
- AuditorTAAD, LLP, Diamond Bar, CA PCAOB ID 5854; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceMay 2, 20161
- Filings118 in all: 6-K (16), F-1/A (12), UPLOAD (9), POS AM (8), 10-Q (7), 8-K (7), CORRESP (7), SC 13D (7)1
All 28 form types
20-F (6), NT 20-F (6), 3 (3), EFFECT (3), SC 13D/A (3), 10-K (2), 10-Q/A (2), 4 (2), 424B3 (2), F-1 (2), NT 10-K (2), NT 10-Q (2), SC 13G (2), SC 13G/A (2), 10-12G (1), 20-F/A (1), 8-A12B (1), DEF 14C (1), PRE 14C (1), PRER14C (1)
- Latest filingsAnnual report (20-F) Nov 7, 2024
Quarterly report (10-Q) Oct 25, 2018
Latest 8-K (8-K) Aug 28, 2018
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Ordinary Shares |
From the cover page of the 20-F filed Nov 7, 2024 (Section 12(b) of the Exchange Act).4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARJames M. Cassidy, President
- 11SEC EDGARJames K. McKillop, Vice President
- 12
- 13
- 14
- 15
- 16
- 17
- 18